NZ598468A - Floating microgranules - Google Patents

Floating microgranules

Info

Publication number
NZ598468A
NZ598468A NZ598468A NZ59846810A NZ598468A NZ 598468 A NZ598468 A NZ 598468A NZ 598468 A NZ598468 A NZ 598468A NZ 59846810 A NZ59846810 A NZ 59846810A NZ 598468 A NZ598468 A NZ 598468A
Authority
NZ
New Zealand
Prior art keywords
active ingredient
alkaline agent
group
core
carbonate
Prior art date
Application number
NZ598468A
Other languages
English (en)
Inventor
Pascal Suplie
Christophe Lebon
Original Assignee
Debregeas Et Associes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debregeas Et Associes Pharma filed Critical Debregeas Et Associes Pharma
Publication of NZ598468A publication Critical patent/NZ598468A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
  • Glanulating (AREA)
NZ598468A 2009-08-12 2010-08-11 Floating microgranules NZ598468A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0955641A FR2949061B1 (fr) 2009-08-12 2009-08-12 Microgranules flottants
PCT/FR2010/051691 WO2011018582A2 (fr) 2009-08-12 2010-08-11 Microgranulés flottants

Publications (1)

Publication Number Publication Date
NZ598468A true NZ598468A (en) 2015-05-29

Family

ID=42115979

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598468A NZ598468A (en) 2009-08-12 2010-08-11 Floating microgranules

Country Status (34)

Country Link
US (1) US8916202B2 (https=)
EP (1) EP2464333B1 (https=)
JP (1) JP6068142B2 (https=)
KR (2) KR20170119743A (https=)
CN (1) CN102548541B (https=)
AR (1) AR077864A1 (https=)
AU (1) AU2010283608B9 (https=)
BR (1) BR112012003289B1 (https=)
CA (1) CA2771053C (https=)
CL (1) CL2012000376A1 (https=)
CY (1) CY1118119T1 (https=)
DK (1) DK2464333T3 (https=)
EA (1) EA023532B1 (https=)
ES (1) ES2588430T3 (https=)
FR (1) FR2949061B1 (https=)
HR (1) HRP20161149T1 (https=)
HU (1) HUE030027T2 (https=)
IL (1) IL218072A (https=)
IN (1) IN2012DN01864A (https=)
LT (1) LT2464333T (https=)
MA (1) MA33523B1 (https=)
MX (1) MX2012001878A (https=)
NZ (1) NZ598468A (https=)
PE (1) PE20120805A1 (https=)
PL (1) PL2464333T3 (https=)
PT (1) PT2464333T (https=)
SG (1) SG180305A1 (https=)
SI (1) SI2464333T1 (https=)
SM (1) SMT201600347B (https=)
TN (1) TN2012000068A1 (https=)
TW (1) TWI478731B (https=)
UA (1) UA107361C2 (https=)
WO (1) WO2011018582A2 (https=)
ZA (1) ZA201201711B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9321956B2 (en) 2012-11-28 2016-04-26 Halliburton Energy Services, Inc. Methods for hindering the settling of particulates in a subterranean formation
US9790774B2 (en) 2014-01-02 2017-10-17 Halliburton Energy Services, Inc. Generating and maintaining conductivity of microfractures in tight formations by generating gas and heat
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2017018996A1 (en) 2015-07-24 2017-02-02 Halliburton Energy Services, Inc. Microbubbles for heat and/or gas generation in subterranean formations
US10301917B2 (en) 2015-07-24 2019-05-28 Halliburton Energy Services, Inc. Microbubbles for treatment chemical delivery in subterranean formations
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3737353A1 (en) 2017-12-18 2020-11-18 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126216A1 (en) 2017-12-18 2019-06-27 Tris Phama, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337919B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
NL2024652B1 (en) * 2020-01-10 2021-09-07 Stabican B V Process for preparing cannabinoid-containing particles
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276418A (en) * 1975-12-19 1977-06-27 Microbial Chem Res Found Method of preparing foamable micro-capsule preparations
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6214386B1 (en) * 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
JP3447042B2 (ja) 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
DK1140061T3 (da) 1998-12-23 2003-08-25 Orphan Medical Inc Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
BR0212019A (pt) 2001-08-06 2005-08-09 Euro Celtique Sa Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829932B1 (fr) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
BR0314036A (pt) 2002-09-04 2005-07-12 Ranbaxy Lab Ltd Apresentações farmacêuticas com mascaramento de sabor e processo para sua preparação
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US20050214372A1 (en) 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
CN101534808A (zh) 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
HUE053838T2 (hu) * 2005-08-24 2021-07-28 Endo Pharmaceuticals Inc Nyújtott felszabadulású nabulfin-készítmények
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
EP1962844A2 (en) * 2005-12-20 2008-09-03 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
FR2938431B1 (fr) * 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments

Also Published As

Publication number Publication date
HRP20161149T1 (hr) 2016-11-18
IN2012DN01864A (https=) 2015-08-21
AU2010283608B2 (en) 2015-07-30
MX2012001878A (es) 2012-06-01
US8916202B2 (en) 2014-12-23
CL2012000376A1 (es) 2013-01-04
JP6068142B2 (ja) 2017-01-25
PL2464333T3 (pl) 2016-12-30
CA2771053A1 (fr) 2011-02-17
WO2011018582A2 (fr) 2011-02-17
ZA201201711B (en) 2012-11-28
UA107361C2 (en) 2014-12-25
WO2011018582A3 (fr) 2011-05-19
PT2464333T (pt) 2016-10-03
MA33523B1 (fr) 2012-08-01
SMT201600347B (it) 2016-11-10
CY1118119T1 (el) 2017-06-28
IL218072A (en) 2016-08-31
SG180305A1 (en) 2012-06-28
BR112012003289A2 (pt) 2020-08-11
BR112012003289B1 (pt) 2021-07-13
EA023532B1 (ru) 2016-06-30
TW201127419A (en) 2011-08-16
CN102548541A (zh) 2012-07-04
CA2771053C (fr) 2017-05-02
KR20170119743A (ko) 2017-10-27
TN2012000068A1 (fr) 2013-09-19
KR20120050477A (ko) 2012-05-18
FR2949061A1 (fr) 2011-02-18
EP2464333A2 (fr) 2012-06-20
AR077864A1 (es) 2011-09-28
SI2464333T1 (sl) 2016-10-28
IL218072A0 (en) 2012-04-30
DK2464333T3 (en) 2016-10-03
JP2013501762A (ja) 2013-01-17
US20120207843A1 (en) 2012-08-16
ES2588430T3 (es) 2016-11-02
LT2464333T (lt) 2016-09-12
HK1172824A1 (en) 2013-05-03
EA201200269A1 (ru) 2012-11-30
CN102548541B (zh) 2015-03-11
HUE030027T2 (en) 2017-04-28
AU2010283608B9 (en) 2015-08-27
TWI478731B (zh) 2015-04-01
PE20120805A1 (es) 2012-07-25
FR2949061B1 (fr) 2013-04-19
AU2010283608A1 (en) 2012-03-29
EP2464333B1 (fr) 2016-06-29

Similar Documents

Publication Publication Date Title
NZ598468A (en) Floating microgranules
JP2013501762A5 (https=)
JP5266048B2 (ja) （ｓ）−ｎ−メチルナルトレキソン、その合成方法およびその医薬用途
WO2004037004A3 (en) Encapsulated functional bakery ingredients
EP2048948A4 (en) LIQUID COMPOSITIONS OF CALCIUM ACETATE
CA2383537A1 (en) Method for manufacturing fatty acid calcium salts from high glyceride content oils
WO2008012329A3 (en) Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
WO2008024139A3 (en) Inhibitors of fatty acid amide hydrolase
PT1976532E (pt) Inibidor de ação rápida da secreção de ácido gástrico
BRPI0707334A8 (pt) formulação de cápsula de gelatina mole e método para estabilização de um composto 15-ceto-prostaglandina
EP1803803A3 (en) Cleaning compounds and method and system for using the cleaning compound
WO2007072495A3 (en) Coated tablets having prolonged gastric retention
WO2008035380A3 (en) An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts
WO2004014310A3 (en) Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
WO2011015305A3 (de) Antibackmittel für harnstoffbasierte düngemittel, düngemittelformulierungen mit diesem antibackmittel und verfahren zu deren herstellung
JP2009507497A5 (https=)
WO2003050071A8 (en) Process for the preparation of methionine
WO2007086541A3 (en) Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
WO2006053564A3 (en) Stabilisation of granules comprising active compounds
ZA200709852B (en) Spiro-benzimidazoles as inhibitors of gastric acid secretion
HK1047927A1 (zh) 脂肪酸合成酶抑制剂
EP1538897A4 (en) METHOD FOR CHANGING THE FATTY SURFACE COMPOSITION OF MILK
CA2239331C (en) Pharmaceutical tablets comprising cefuroxime axetil
WO2007054771A3 (en) An improved process for the preparation of cilastatin and sodium salt
WO2008022745A8 (de) Formulierungen zur kontrollierten freisetzung agrochemischer wirkstoffe

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 AUG 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20151223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2018 BY CPA GLOBAL

Effective date: 20170629

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2019 BY CPA GLOBAL

Effective date: 20180712

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2020 BY DENNEMEYER + CO.

Effective date: 20190805

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2021 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20200804

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2022 BY DENNEMEYER + CO.

Effective date: 20210802

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2023 BY DENNEMEYER + CO. SARL.

Effective date: 20220801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2024 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20230807

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2025 BY MS. PETRA OLK

Effective date: 20250204

LAPS Patent lapsed